For the year ending 2025-12-31, ASPN had -$62,706K decrease in cash & cash equivalents over the period. -$4,577K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -389,552 |
| Depreciation | 45,157 |
| Amortization of debt issuance costs | 3,637 |
| Provision for bad debt | 3,538 |
| Stock-based compensation expense | 8,628 |
| Impairment of property, plant and equipment | 291,626 |
| Loss on disposal of property, plant and equipment | -18,162 |
| Deferred taxes | -416 |
| Reduction in the carrying amount of operating lease right-of-use assets | -3,534 |
| Accounts receivable | -70,296 |
| Inventories | -9,302 |
| Prepaid expenses and other assets | -18,172 |
| Accounts payable | -19,453 |
| Accrued expenses | -23,310 |
| Deferred revenue | -940 |
| Operating lease and other liabilities | -5,509 |
| Net cash provided by (used in) operating activities | 32,872 |
| Capital expenditures | 37,449 |
| Net cash used in investing activities | -37,449 |
| Proceeds from employee stock option exercises | 1,718 |
| Payments made for employee restricted stock tax withholdings | 765 |
| Fees and issuance costs from registered direct offering of common stock | 28 |
| Proceeds from employee stock purchase plan | 176 |
| Repayment of term loan | 26,000 |
| Repayment of revolving line of credit | 28,000 |
| Repayment of lease and other finance obligations | 5,230 |
| Net cash (used in) provided by financing activities | -58,129 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -62,706 |
| Cash, cash equivalents and restricted cash at beginning of period | 221,276 |
| Cash, cash equivalents and restricted cash at end of period | 158,570 |
ASPEN AEROGELS INC (ASPN)
ASPEN AEROGELS INC (ASPN)